SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

OPFOLDA

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approved September 28, 2023; EMA approved).
Why 4/10
OPFOLDA is already FDA-approved (September 28, 2023) and commercially marketed; there is no pending PDUFA, pivotal readout, or AdComm in the next 12 months. As an approved drug with no imminent binary regulatory catalyst, per the rubric the impactScore is capped at 3-5. It is one of several commercial products in BioMarin's diversified portfolio, not a single-asset binary, so the score is set at 4.
Actionable Insight NEUTRAL

OPFOLDA (as part of POMBILITI + OPFOLDA) is already approved and generating revenue for BioMarin. The next catalyst to watch is the commercial ramp: quarterly revenue growth and market share gains against Sanofi's Nexviazyme in the Pompe disease market. BioMarin's Q3 2026 earnings (reported Nov 2, 2026) showed POMBILITI + OPFOLDA benefiting from supply constraints on competing therapies, but full-year guidance was trimmed slightly. No binary regulatory catalyst is scheduled.

Price Chart

Loading chart...

Executive Summary

OPFOLDA (miglustat) is an oral enzyme stabilizer used in combination with POMBILITI (cipaglucosidase alfa-atga, an IV enzyme replacement therapy) for adults with late-onset Pompe disease. The FDA approved the combination on September 28, 2023. Originally developed by Amicus Therapeutics, the drug was acquired by BioMarin Pharmaceutical (NASDAQ: BMRN) through a $4.8 billion all-cash acquisition completed April 27, 2026. OPFOLDA is already commercialized in the U.S. and Europe, competing primarily with Sanofi's Nexviazyme. Five-year Phase 3 extension data presented in October 2026 showed durable efficacy. For a non-medical investor, OPFOLDA is a revenue-generating asset within BioMarin's broader rare-disease portfolio, with no pending binary regulatory catalyst; the investment thesis hinges on commercial execution and market share growth.

How It Works

OPFOLDA (miglustat) is an enzyme stabilizer taken as an oral capsule. In Pompe disease, patients lack a working enzyme that breaks down glycogen (a stored sugar) in muscle cells, causing muscle weakness and breathing problems. OPFOLDA is designed to stabilize the replacement enzyme (POMBILITI, given by IV infusion) in the bloodstream, keeping it active longer so it can reach muscle tissue and break down glycogen more effectively. It is always used together with POMBILITI as a two-component therapy.

Trial Status

OPFOLDA (with POMBILITI) was approved by the FDA in September 2023 based on the Phase 3 PROPEL study (NCT03729362). Five-year open-label extension data (ATB200-07; NCT04138277) were presented at the World Muscle Society congress in October 2026, showing durable efficacy: ERT-naive patients improved six-minute walk distance by +10.5% at year 5, and ERT-experienced patients stabilized (+0.7%).

The Two-Sided Case

▲ Bull Case5
OPFOLDA (miglustat) is part of a two-component therapy (with POMBILITI) that is FDA-approved and EMA-approved for late-onset Pompe disease, a rare, life-threatening disorder with limited treatment options and a growing market estimated at $2.04 billion in 2026.
Five-year Phase 3 open-label extension data presented at WMS October 2026 showed durable long-term efficacy: ERT-naive patients improved six-minute walk distance by +10.5% at year 5, and ERT-experienced patients stabilized (+0.7%), reinforcing the drug's long-term value proposition.
BioMarin acquired Amicus Therapeutics for $4.8 billion (completed April 27, 2026), adding POMBILITI + OPFOLDA and GALAFOLD. Q3 2026 was the first quarter with a full contribution: total revenue hit $1.025 billion (up 32% YoY), with Metabolic Conditions revenue up 44% YoY driven by these additions.
Analyst consensus is bullish: 27 analysts give a mean price target of $91.56 (57.4% implied upside from $58.16), with 17 buy/strong-buy ratings, 8 hold, and 0 sell. Major firms like Morgan Stanley, JP Morgan, and Barclays maintain Overweight ratings.
The global Pompe disease market is projected to grow at 6-10% CAGR through the early 2030s, driven by newborn screening expansion and next-generation ERT adoption, providing a long tail for POMBILITI + OPFOLDA.
▼ Bear Case4
OPFOLDA faces direct competition from Sanofi's Nexviazyme (avalglucosidase alfa), which has a broader approved age range and is also indicated for late-onset Pompe disease, creating a market share battle.
Five-year Phase 3 extension data showed only a +0.7% change in six-minute walk distance for ERT-experienced patients at year 5, suggesting the drug stabilizes rather than improves function in patients who have already been on other enzyme replacement therapy.
BioMarin lowered its full-year 2026 revenue guidance to $3.8-$3.9 billion (from prior expectations), citing roughly $70 million in deferred international orders, which may signal lumpy adoption.
The bull/bear evidence checklist for BMRN shows a net bearish signal over 90 days, with elevated short-sale volume (z-score 1.63), several institutional exits/severe trims including Citadel (near-exit, -75.1%), Point72 (exit), and Wellington (exit), plus an insider sale of $1.16M by the EVP/Chief Legal Officer.

Upcoming Catalysts

  • Quarterly revenue growth and commercial uptake updates (next: Q4 2026 / full-year 2026 earnings, expected early February 2027)
  • Potential label expansion or pediatric indication (no publicly announced filing as of November 2026)
  • Market share dynamics versus Sanofi's Nexviazyme in the Pompe disease market

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 12

Hover a chip for the title
1 biomarin.com2 biomarin.com3 biomarin.com4 accessdata.fda.gov5 drugs.com6 ema.europa.eu7 pombilitiopfoldahcp.com8 fiercepharma.com9 prnewswire.com10 investors.biomarin.com11 marketbeat.com12 novapharmanews.com